14 results
P
cancer patients
I/C
immune checkpoint inhibitors (ICIs), higher PIV
O
shorter overall survival (OS) and progression-free survival (PFS)
P
Yu X, Xu R, Zhang Z, Yang Y, Deng F
I/C
extra-short implants (≤ 6 mm), longer implants (≥ 8 mm)
O
bone augmentation
P
Fenland Study, FinnGen Study, PLCO Atlas Project, Pan-UK Biobank
I/C
lactase-phlorizin hydrolase (LPH), colorectal cancer (CRC)
O
direct causal relationship
P
pediatric, adult
I/C
smokeless tobacco (SLT), oral potentially malignant disorders (OPMDs), head and neck cancer (HNC)
O
prevalence of use, association
P
people being investigated for tuberculosis
I/C
Xpert MTB/RIF, smear microscopy
O
mortality, proportion of participants starting tuberculosis treatment who had a successful treatment outcome, proportion of participants who were treated for tuberculosis, proportion of participants with bacteriological confirmation who were lost to follow-up pre-treatment, proportion of treated participants who had bacteriological confirmation
P
patients with oncologic and nononcologic indications
I/C
FAP-specific PET imaging and radionuclide therapy, detection rates of FAPI avidity
O
high radiolabeled FAPI avidity as early as 10 minutes after administration in primary sites of various malignant tumors
P
patients with chronic myeloid leukemia (CML)
I/C
ponatinib, a third-generation TKI, current first-line TKIs
O
effectiveness, feasibility, and safety of ponatinib in real-life clinical management of CML
P
human tumors
I/C
LINC00963 expression, poor overall survival
O
MSI, TMB, MMR
P
tumour tissue, non-tumour tissue
I/C
pharmacological or genetic inhibition of SOAT, tumour tissue vs non-tumour tissue
O
significantly smaller tumours of all types, increased tumour apoptosis, CD8+ lymphocyte infiltration and cytotoxicity, reduced proliferation, reduced metastasis
P
CHROMATRYPSIN C
I/C
CHROMATRYPSIN C, CHROMATRYPSIN C
O
CHRONIC PANCREATITIS